NeuroOne’s OneRF Ablation System Reaches a New Milestone
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has reported a notable advance in neurological care: its OneRF Ablation System was used in a first-of-its-kind procedure at a leading medical center. In a single patient, the system enabled forty-four ablations, a number that points to meaningful potential for people living with neurological disorders who need precise, targeted treatment.
What It Meant for the Patient
The case was led by neurosurgeon Dr. Michael Staudt. Over two days, his team used six implanted electrodes to access and treat the brain regions linked to the patient’s condition. Following the series of ablations, the patient is reportedly seizure-free and has seen noticeable improvements in mood and cognitive functions, including memory. While every case is unique, this result underscores how carefully delivered, minimally invasive care can support recovery and daily quality of life.
A Procedure Built Around Comfort and Control
According to Dr. Staudt, the patient tolerated the ablation sessions remarkably well. That matters. Because the OneRF system can be used at the bedside, patients remain in a familiar setting, which can reduce stress and help teams monitor responses in real time. Immediate clinical checks pointed to a positive course for this patient, a reminder that the way technology is delivered—the pacing, the environment, the control it gives the surgical team—can be as important as the technology itself.
Strengthening a Commitment to Advanced Care
NeuroOne’s CEO, Dave Rosa, shared his excitement about the outcome and what it may signal. He noted that performing forty-four ablations in one patient is unusual compared to what is commonly described in the literature, and he credited the system’s design for enabling that breadth of treatment. While more experience will shape how the system is used over time, Rosa’s comments point to a simple idea: if clinicians have tools that are precise, efficient, and patient-friendly, more people may be candidates for effective treatment.
How OneRF Fits in NeuroOne’s Portfolio
The OneRF Ablation System builds on NeuroOne’s thin film electrode technologies, which are engineered for both diagnostic use and radiofrequency (RF) ablation. In practice, that means the same platform that helps identify problem areas can also be used to treat them, giving care teams more options at each step. By pairing high-resolution electrodes with ablation capability, NeuroOne aims to support a more streamlined approach to complex neurological conditions.
Market Potential and Where Growth Could Come From
The broader context matters, too. The market for brain ablation technologies is estimated at over $100 million worldwide, and needs continue to surface in patient populations that aren’t fully served by current options. With technologies like OneRF, NeuroOne positions itself to contribute to that space—both by improving individual patient outcomes and by helping shape the standard of care in procedures where precision and repeatability are essential.
The Road Ahead
NeuroOne continues to focus on minimally invasive, high-definition neuromodulation solutions. The company is evaluating how the OneRF Ablation System might apply across different clinical areas. While this case centers on seizures, the same platform approach may be relevant to other conditions, from epilepsy to chronic pain, where targeted, image-guided intervention is key. The work is ongoing; the aim is steady: give clinicians better tools and patients a clearer path forward.
Frequently Asked Questions
What is the OneRF Ablation System?
The OneRF Ablation System is a NeuroOne device designed for precise radiofrequency ablation in neurological care. It’s built to work with thin film electrodes that can help both identify and treat the areas contributing to a patient’s symptoms.
How many ablations were completed in this case?
Forty-four ablations were performed in a single patient. The team completed them over two days, using six implanted electrodes to reach the targeted regions.
What results were observed in the patient?
Following the procedure, the patient is reportedly seizure-free and has experienced improvements in mood and memory. Immediate clinical evaluations suggested a positive trajectory, according to the care team.
Who led the ablation procedure?
The procedure was led by neurosurgeon Dr. Michael Staudt, who oversaw the two-day series of ablations and reported that the patient tolerated the sessions well.
What is NeuroOne’s mission?
NeuroOne Medical Technologies Corporation aims to deliver innovative, minimally invasive solutions—such as high-definition electrodes and ablation tools—that can improve surgical outcomes for people with neurological disorders.
